comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - International metastatic - Page 1 : comparemela.com
Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC
Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.
United-states
Tennessee
America
Brian-rini
International-metastatic
Vanderbilt-ingram-cancer-center
Ingram-professor-of-cancer-research
Database-consortium
Highert-cell
Clinical-trials
Ingram-professor
Cancer-research
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC
Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.
Massachusetts
United-states
Boston
Dana-farber-cancer-institute
America
Toni-choueiri
Nancy-kohlberg
Memorial-sloan-kettering-cancer-center
International-metastatic
Database-consortium
Professor-of-medicine-at-harvard-medical-school
Lank-center
ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study
ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
United-states
Toronto
Ontario
Canada
Washington
Georgetown-university
District-of-columbia
Chicago
Illinois
American
Michael-atkins
Michaelb-atkins
DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC
The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.
California
United-states
Sumanta-kumar-pal
Bladder-cancer-disease-team
Kidney-cancer-program
Database-consortium
International-metastatic
Medical-oncology
Therapeutics-research
Hope-comprehensive-cancer-center
ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC
Although the overall survival miss won't cost Bavencio its FDA approval, it puts the drug further behind rival PD-1 combos from Merck & Co. and BMS.
New-york
United-states
American
Merck-keytruda
Keytruda-lenvima
Peter-guenter
Exelixi-cabometyx
Merck-kgaa-bavencio
International-metastatic
Merck-kgaa
Bristol-myers-squibb
Pfizer
vimarsana © 2020. All Rights Reserved.